Jeuveau — nicknamed “Newtox” — is a neuromodulator in the same family as Botox, made by Evolus and FDA-approved in 2019 for frown lines.
Jeuveau — nicknamed “Newtox” — is a neuromodulator in the same family as Botox, made by Evolus and FDA-approved in 2019 for frown lines. It’s marketed as the modern, affordable Botox alternative, and at the molecular level it’s the closest match to Botox of any competitor.
Jeuveau — nicknamed “Newtox” — is a neuromodulator in the same family as Botox, made by Evolus and FDA-approved in 2019 for frown lines. It’s marketed as the modern, affordable Botox alternative, and at the molecular level it’s the closest match to Botox of any competitor. This guide covers what Jeuveau is, how it works, how long it lasts, what it costs, its safety, and how it compares to the other toxins.
Jeuveau (prabotulinumtoxinA-xvfs) is an injectable botulinum toxin type A that relaxes the muscles causing frown lines — the same mechanism as Botox and Dysport. It’s made by Evolus (and produced by Daewoong) and, unlike the older toxins that began as medical drugs, Jeuveau was designed from the start exclusively for aesthetics. The “Newtox” nickname came from social media as it gained popularity with younger, first-time patients.
Quick comparison — Active ingredient — Jeuveau: PrabotulinumtoxinA-xvfs (botulinum toxin type A) | Maker — Jeuveau: Evolus (produced by Daewoong) | FDA approval — Jeuveau: 2019 — moderate-to-severe glabellar (frown) lines, adults | Nickname — Jeuveau: “Newtox” | Dosing — Jeuveau: ~1:1 with Botox (clinically comparable units) | Onset — Jeuveau: ~2–3 days (slightly faster than Botox) | Duration — Jeuveau: 3–4 months | Positioning — Jeuveau: Aesthetics-only; typically 20–30% cheaper than Botox.
Like every neuromodulator, Jeuveau blocks the nerve signal that tells a muscle to contract, so the overlying skin stops creasing and frown lines soften. It uses a roughly 900 kDa complex — the same size as Botox’s — with human serum albumin (Evolus brands its process “Hi-Pure”). That structural similarity is why it doses 1:1 with Botox. It’s a muscle relaxer, not a volumizer, so it treats movement lines rather than lost volume; for volume you’d want dermal fillers (see Botox vs dermal fillers).
Jeuveau is FDA-approved specifically for frown lines (glabellar “11s”) — the same starting point as Botox. Because it’s aesthetics-only, it has no therapeutic approvals (no migraine, sweating, or muscle-disorder uses), unlike Botox. As with the other toxins, injectors may use it off-label for other movement lines such as forehead wrinkles and crow’s feet, but on-label it’s a frown-line treatment.
About 3 to 4 months — essentially the same as Botox. Some patients report results stretching toward five months, but the typical range matches the standard toxins. (For markedly longer duration, Daxxify is the outlier at ~6 months — see Botox vs Daxxify.) Onset is quick, often 2–3 days, a touch faster than Botox, with peak effect around two weeks. Like all toxins it wears off gradually and can’t be reversed.
Price is Jeuveau’s headline advantage. It’s dosed 1:1 with Botox but typically priced 20–30% lower per unit, which can make a frown-line treatment meaningfully cheaper. Evolus positions it as the value option, and the discount reflects a competitive pricing strategy, not lower potency or quality. Because it lasts about as long as Botox, that per-unit saving carries through to your annual cost. Compare the neuromodulator math in the Botox cost guide — and as always, be cautious of pricing that seems too good to be true, the same way you’d weigh bargain-priced injectables.
Jeuveau has a safety profile in line with other botulinum toxin type A products. The most common side effects are mild and temporary — headache, injection-site reactions (redness, swelling, bruising), and occasional eyelid droop (ptosis) if the toxin spreads beyond the target muscle. Serious effects are rare. Because it’s the same drug class, its risk profile mirrors Botox’s side effects, and it carries the same FDA class warning about toxin spread. Its risks differ from filler side effects, which center on the product’s physical presence. A qualified injector is the best safeguard.
Of all the Botox alternatives, Jeuveau is the closest match — same complex size, 1:1 dosing, similar onset and duration — so in the chair for frown lines it behaves much like Botox, just cheaper and aesthetics-only. The others each have a twist: Dysport spreads more and starts fast (good for larger areas; see Botox vs Dysport), Daxxify lasts about twice as long, and Xeomin is the “naked” toxin with no accessory proteins. We’ll put it head-to-head in Botox vs Jeuveau.
Jeuveau is a sensible pick if you want a Botox-equivalent result for frown lines at a lower price, or if you like that it’s purpose-built for aesthetics. Because it doses like Botox, switching is straightforward. It’s generally avoided in pregnancy or breastfeeding, with certain neuromuscular disorders, or with an allergy to the ingredients. It only treats movement lines — for volume loss like under-eye hollows or thin lips, fillers are the tool. A consultation confirms whether it fits your goals.
As with any neuromodulator, many people combine Jeuveau with dermal fillers in one plan — the toxin relaxes dynamic lines while filler restores volume. A typical combo pairs Jeuveau on the frown and forehead with lip filler or a cheek filler like Juvederm or Restylane (compared in Juvederm vs Restylane). The two solve different problems, so budget for both using the Botox and dermal fillers cost guides, and note that fillers carry their own longevity timelines.
As with every neuromodulator, results and safety hinge on the injector’s skill and dosing, not the brand on the vial. Choose a licensed, experienced provider (a board-certified dermatologist or plastic surgeon, or a trained injector under medical supervision) who uses genuine Jeuveau and can explain whether it or another toxin best suits your goals and budget. Find and compare qualified injectors near you, or start at the Botox hub for the neuromodulator basics.